Again, CXCL12/CD66b positivity was confirmed to represent an independent favorable RFS predictor in primary cancer biopsies (HR 0.15; 95% CI 0.05–0.43; p =  < 0.001, 95% HR 0.13; CI 0.04–0.42; p = 0.001, respectively) (Table 3B). Here, CXCL12 is linked to cancer.